The DNA-damaging agent bleomycin arrests the cell cycle at the G2 phase of Jurkat cells defective in the G1 checkpoint, and microtubule-acting colchicine arrests it at the M phase. Boromycin itself, an actinomycete metabolite, showed no effect on the cell cycle status of Jurkat cells at least up to 340nM. However, the compound (3.4-340nM) was found to abrogate bleomycin-induced G2 arrest even at 3.4nM, resulting in a drastic decrease in cells at the G2 phase and increase in cells at the subG1 phase. On the other hand, boromycin did not show any effect on the colchicine-induced M phase arrest in Jurkat cells, nor on the cell cycle status of the bleomycin-treated or -untreated HUVEC, normal cells conserving both G1 and G2 checkpoints. Furthermore, boromycin potentiated anti-tumor activity of bleomycin in scid mice inoculated with Jurkat cells. These data suggest that boromycin disrupts the cell cycle at the G2 checkpoint of cancer cells selectively, leading to sensitization of cancer cells to anti-cancer reagents.
DNA damage induces signal transduction pathways known as checkpoints, which delay cell cycle progression to repair DNA1). Checkpoints arrest cells in the G1 phase to prevent replication of damaged DNA and in the G2 phase to prevent the segregation of damaged chromosomes during mitosis. Normal human cells can repair DNA in the G1 and G2 phases, whereas most cancer cells have mutations in genes involved in the G1 checkpoint, such as p53, p16TNK4, or Rb2), and can repair DNA only in the G2 phase.
Accordingly, disruption of the G2 checkpoint in cancer cells is expected to increase sensitivity to DNA-damaging reagents like bleomycin, cisplatin and camptothecin, resulting in selective cell death of cancer cells by accumulation of mutation in genes. Therefore, the G2 checkpoint is a potential target for development of a novel therapy against intractable cancers.
In the G2 checkpoint, DNA damage activates the ATM (ataxia telangiectasia-mutated) and ATR (A-T and rad3-related) members of the phosphoinositide kinase family3,4). (Fig. 2C) , respectively.
These data indicated that boromycin alone shows no effect on the cell cycle of Jurkat cells. When Jurkat cells were distributed in subG1, G1, S and G2/M phases were 16.7%, 2.7%, 9.1% and 65.5%, respectively ( Fig. 2A) , indicating that Jurkat cells were arrested at the G2 phase by bleomycin. In combination with boromycin (3.4-340nM), the cell cycle pattern began to change shape even at 3.4nM.
The distribution ratio in subGl was drastically increased to 52.9-57.2%, indicating that boromycin induced cell death in DNA-injured Jurkat cells. On the other hand, when
Jurkat cells were incubated in the presence of colchicine, the distribution ratios of subG1, G1, S and G2/M phases were 42.2%, 2.1%, 2.9% and 50.6%, respectively (Fig. 2B ).
In combination with boromycin (3.4-340nM), the cell cycle distributions were almost unchanged; 42.7% of colchicine-treated Jurkat cells remained in G2/M phase at 340nM boromycin. These findings strongly suggested that boromycin abrogated DNA damage-induced G2 arrest in Jurkat cells.
The effect of boromycin was evaluated using a normal HUVEC line (Fig. 3) . The distribution ratios of subG1, G1, S and G2/M phases in a cell cycle without a compound G2 phase slightly decreased from 50.4% to 36.9%, correspondingly the G1 ratio increased from 28.2% to 34.4%, and there was no change in subG 1 ratios. These results indicated that boromycin abrogated G2 arrest but not G1 arrest in HUVEC, and showed no effect on the survival of normal cells.
Jurkat cells were cultured for 20 hours in the absence or presence of boromycin (100nM), and the amounts of total Cdc2 and phosphorylated Cdc2 were analyzed (Fig. 4) . The phosphorylated Cdc2 was very low or almost undetectable in the absence of boromycin (control), whereas total Cdc2 injection of Jurkat cells. Bleomycin (25mg/kg) and boromycin (0.2mg/kg) were administered by i.p. injections every 6 days and every 3 days, respectively, for 2 weeks. Weights of tumors were measured 18 days after initial treatment, and average tumor weight was calculated. The significance of difference of the means was determined as described in the "Materials and Methods".
Discussion
As demonstrated in this paper, boromycin inhibited bleomycin-induced G2 phase arrest, leading to cell death in Jurkat cells, but showed no effect on colchicine-induced M phase arrest. These data suggested that boromycin abrogated the G2 checkpoint in the cell cycle specifically.
To confirm this point, Cdc2 phosphorylation levels involved in the G2 checkpoint were measured. Boromycin reduced the phosphorylation levels of Cdc2 driven by bleomycin-induced DNA damage (Fig. 4) , and the cells moved to the M phase compulsorily. In HUVEC, a normal cell line, bleomycin induced G1 and G2 arrests, and in combination with boromycin, induced a slight decrease in G2 phase cells and increase in G1 and S phase cells (Fig.   3 ). Therefore, we concluded that boromycin specifically injections every 3 days for 2 weeks (Fig. 5) 
